GSK/Novartis Support For Benefiber Claims Too Thin To Convince NARB
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
Referring to rather than providing two studies was GSK/Novartis' downfall in arguing before the National Advertising Review Board to support Benefiber regularity claims. GSK/Novartis questions the panel’s "refusal to accept the full translations of two confirmatory studies referred to in the record."
You may also be interested in...
Pepto-Bismol Ultra Works As Name But Not For P&G To Claim Twice Original Product's Strength
To understand how Pepto-Bismol Ultra could be considered twice as strong as original as stated on packaging, consumers would need to "carefully review the Drug Facts on the back of both" products and "recognize that the active ingredient in both products is 525 mg of bismuth subsalicylate" but Ultra's dose is half original's.
Ingredient Studies Again Not Enough For New Nordic Product Claims – NAD
Two months after referring advertising for its Hair Volume supplement to FTC, NAD zeroes in on claims for New Nordic USA's Skin Care Collagen Filler supplement. NAD says the firm should discontinue anti-wrinkle and collagen-building claims in the absence of reliable evidence from well-controlled human clinical testing.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”